Corcept and Halozyme are Top Holdings in U.S. Small-Cap ETFs
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics and Halozyme Therapeutics are listed as top holdings in the JPMorgan BetaBuilders U.S. Small Cap Equity ETF and the Schwab U.S. Small-Cap ETF, according to reports from October 15, 2026. These ETFs track U.S. small-cap indexes but vary in cost and portfolio breadth.
From fool.com
Why it matters
The reports note that small-cap stocks often offer higher growth potential compared to large-cap peers, though they carry greater volatility and sector-specific weightings. The Schwab fund, for instance, has a low expense ratio of 0.03% compared to the 0.09% charged by the JPMorgan fund.
From fool.com
Who's involved
- Corcept TherapeuticsAmerican pharmaceutical company identified as a top holding in small-cap ETFs
- Halozyme TherapeuticsPharmaceutical company identified as a top holding in small-cap ETFs
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
Nothing else this week.
-
Halozyme Therapeutics
Nothing else this week.